Table 4.

Outcomes of patients under HR or TACE for various PVTT types

Study(year)	Treatment	Type of PVTT	Patients	Median OS(months)	1-year(%)	2-year(%)	3-year(%)	5-year(%) of Survival rates
Fan 2001 [20]	HR	Type II	58	13.0	59.7	NA	27.4	8.8
		Type III	16	8.0	29.4	NA	14.3	11.1
	TACE	Type II	12	5.0	16.7	NA	8.3	0
		Type III	6	5.5	33.3	NA	0	0
Peng 2012 [12]	HR	Type I	27	NA	81.5	NA	51.2	37.9
		Type II	68	NA	46.3	NA	17.2	17.2
		Type III	83	NA	32.5	NA	3.6	3.6
		Type IV	23	NA	21.7	NA	0	0
	TACE	Type I	64	NA	41.1	NA	8.9	3.6
		Type II	136	NA	37.9	NA	6.0	0
		Type III	166	NA	36.1	NA	4.2	0
		Type IV	46	NA	30.4	NA	4.3	0
Liu K 2014 [17]	HR	Type I	12	30.0	100.0	66.7	30.0	NA
		Type II	21	18.2	66.7	32.6	0	NA
		Type III	8	8.9	25.0	0	0	NA
	TACE	Type I	24	19.7	74.8	30.8	12.8	NA
		Type II	32	10.8	25.9	9.7	0	NA
		Type III	16	7.4	25.0	0	0	NA
Lee 2016 [13]	HR	Type I	16	NA	71.4	54.5	54.4	NA
		Type II	8	NA	35.0	0	0	NA
	TACE	Type I	12	NA	50.0	25.0	16.7	NA
		Type II	14	NA	35.7	7.1	0	NA
Wang 2016 [11]	HR	Type I	122	14.7 (10.7-18.7)	57.2	36.1	21.0	10.0
		Type II	187	12.1 (10.0-14.2)	50.8	31.0	22.3	13.3
		Type III	171	6.2 (4.4-7.9)	36.3	17.4	8.2	2.6
	TACE	Type I	45	8.7 (4.1-13.3)	40.0	17.3	7.3	0
		Type II	187	5.3 (4.4-6.2)	25.1	9.5	5.3	4.5
		Type III	171	5.2 (3.7-6.6)	28.1	12.1	6.7	5.7